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GM6001Though compromised blood–brain barrier (BBB) is a pathological hallmark of WNV-associated neurological
sequelae, underlying mechanisms are unclear. We characterized the expression of matrix metalloproteinases
(MMP) in WNV-infected human brain microvascular endothelial cells (HBMVE) and human brain cortical
astrocytes (HBCA), components of BBB and their role in BBB disruption. Expression of multiple MMPs was
signiﬁcantly induced in WNV-infected HBCA cells. Naïve HBMVE cells incubated with the supernatant from
WNV-infected HBCA cells demonstrated loss of tight junction proteins, which were rescued in the presence
of MMP inhibitor, GM6001. Further, supernatant from WNV-infected HBCA cells compromised the in vitro
BBB model integrity. Our data suggest astrocytes as one of the sources of MMP in the brain, which mediates
BBB disruption allowing unrestricted entry of immune cells into the brain, thereby contributing to WNV
neuropathogenesis. Because of the unavailability of WNV antivirals and vaccines, use of MMP inhibitors as an
adjunct therapy to ameliorate WNV disease progression is warranted.
© 2009 Elsevier Inc. All rights reserved.Introduction
Although immune surveillance in the brain is a normal physio-
logical response, increased traversing of activated immune cells and
pathogens across the blood–brain barrier (BBB) leads to pathophysio-
logical changes in neuroinﬂammatory diseases such as multiple
sclerosis, cerebral ischemia (Persidsky et al., 2006; Petty and Lo,
2002), bacterial meningitis (BM) and infections with viruses such as
HIV (Kanmogne et al., 2007), human T-lymphotropic virus (Afonso
et al., 2007) and West Nile virus (WNV) (Arjona et al., 2007a; Wang
et al., 2004). Matrix metalloproteinases (MMP), a large family of
endopeptidases, play a major role in leukocyte migration, modulating
cytokine activity and disruption of the BBB (Gearing et al., 1995;
Johnatty et al., 1997; Leppert et al., 2001; Mun-Bryce et al., 2002; Yong
et al., 2007). Excess MMP production and activation is the key
pathophysiological hallmark of several neurodegenerative diseases
(Cunningham, Wetzel, and Rosenberg, 2005; Hu et al., 2007;
Rosenberg, 1995; Rosenberg, 2002). Physiologically, MMP activity is
tightly regulated at the level of gene transcription, pro-enzymeA, Honolulu, HI 96813, USA.
).
ll rights reserved.activation and by the action of tissue inhibitors of MMP (TIMP).
Though the basal levels of MMP expression in the brain are low, under
pathological conditions, MMPs are synthesized by most of the
resident CNS cells such as endothelial cells, astrocytes, microglia and
neurons as well as the inﬁltrating immune cells (Hummel et al., 2001;
Mandal et al., 2003; Rosenberg, 2002).
WNV, an enveloped, single-stranded positive-sense, neurotropic
ﬂavivirus is an important human pathogen that targets neurons to
cause potentially lethal encephalitis (Diamond et al., 2003; Hayes and
Gubler, 2006). Neurological complications such as inﬂammation,
failure of the BBB, and neuronal death contribute to the mortality and
morbidity associated with WNV-induced meningitis. Increased
production of pro-inﬂammatory mediators facilitate WNV neuro-
invasion by compromising the BBB integrity and are associated with
high virus titers in the brain and increased mortality in WNV mouse
models (Arjona et al., 2007b; Wang et al., 2008; Wang et al., 2004).
Recent studies using MMP-9 knock out mouse model provides
important evidence for the role of WNV-induced MMP-9 in opening
of the BBB (Wang et al., 2008). The BBB primarily consists of
microvascular endothelial cells and perivascular astrocytes, separated
by the basementmembrane (Persidsky et al., 2006). The tight junction
proteins (TJP) such as zona occludens (ZO), claudins and occludin, the
main structural basis of BBB integrity, play a key role in the physiology
of the BBB (Persidsky et al., 2006).
Fig. 2. WNV differentially modulates expression of MMP family genes in HBCA cells.
qRT-PCR was conducted on cDNA templates fromWNV- and mock-infected HBCA cells
harvested from days 1–4 after infection to determine the fold-change of (A) MMP-1, -2,
-3 and -9 and (B) TIMP-1, -2 and -3 gene expression. Change in the levels of each gene
was ﬁrst normalized to the GAPDH gene and then the fold-change in infected cells as
compared to corresponding control cells was calculated. Data represent mean of at least
four independent experiments conducted in duplicate.
131S. Verma et al. / Virology 397 (2010) 130–138Though neurons are the prime target of WNV infection, we and
others have previously characterized WNV infection in the BBB cells,
human brain microvascular endothelial (HBMVE) cells and brain
astrocytes (Cheeran et al., 2005; van Marle et al., 2007; Verma et al.,
2009). Recent report documenting the presence of WNV antigen in
the astrocytes of WNV-infected human brain tissue further suggests
the role of these cells in WNV neuropathogenesis (van Marle et al.,
2007). However, our understanding of the cellular mechanisms
associated with WNV-induced BBB disruption, speciﬁcally the
contribution of BBB-associated cells, is limited. Therefore, the aim of
this study was to examine the effect of WNV infection on the
expression proﬁle of MMP family genes in the BBB cells, characterize
their role in disrupting the tight junctions of the BBB and assess the
ability of MMP inhibitor GM6001 in reversing the disruption of an in
vitro BBB model.
Results
Human brain cortical astrocytes cells are susceptible to WNV infection
Brain endothelial cells and astrocytes are the two main
components of the BBB. In this report we demonstrate that the
WNV titer in infected human brain cortical astrocytes (HBCA) cells
peaks (log 7–8 PFU/mL) at day 3 after infection, followed by a sharp
decline (Fig. 1A). Similar to our previous study, we further
conﬁrmed that WNV can efﬁciently replicate in HBMVE cells
(Fig. 1A) (Verma et al., 2009). The speciﬁcity of WNV infection in
HBCA cells was further characterized by immunostaining of HBCA
cells with astrocyte speciﬁc marker, glial ﬁbrillary acidic protein
(GFAP), and WNV antigen (Fig 1B). Almost 100% of cells were found
to be GFAP positive, thereby conﬁrming the purity of these primary
HBCA cells (Fig. 1B, i). Robust staining of WNV antigen was detected
in the cytoplasm of HBCA cells at day 2 after infection (Fig. 1B, ii).
Infected HBCA cells stained with only secondary antibody against
both anti-GFAP (data not shown) and WNV antigen (Fig. 1B, iii) did
not show any immunostaining.
WNV induces mRNA expression of MMP family genes in HBCA cells
The global response of HBMVE and HBCA cells infected with WNV
at multiplicity of infection-5 (MOI-5) was determined at days 1 and
3 after infection by cDNA microarray analysis. Though WNV infection
was robust and comparable in both the cell types, WNV infection did
not alter the expression proﬁle of MMP and TIMP genes in HBMVE
cells at days 1 and 3 after infection (data not shown). Whereas WNV
infection did not induce any MMP family genes in HBCA cells at day
1 after infection, a signiﬁcant increase in the expression of MMP-1Fig. 1.WNV replication kinetics in HBCA cells. (A) WNV titers in infected HBCA and HBMVE
plaque assay using Vero cells. Viral titers expressed as plaque forming units (PFU)/mL of
experiments. (B) HBCA cells grown and ﬁxed on coverslips at day 2 after infection were s
with DAPI (blue). (i) Mock-infected HBCA cells demonstrate GFAP staining in the cytoplas
(iii) WNV-infected HBCA cells stained with secondary antibody, negative control, did not(34-fold) and -3 (26-fold) genes was observed in these cells at day 3
after infection. Increase in the expression of MMP and TIMP in HBCA
cells was further validated by qRT-PCR at different time points after
infection. In concurrence with the microarray data, as seen in Fig. 2A,
MMP-1 and -3 genes expression increased at day 2, and was
signiﬁcantly up-regulated, 20- to 40-fold, at days 3 and 4 after
infection which coincided with the peak in the WNV titers. In
addition, MMP-9 expression demonstrated signiﬁcant increase (9- to
30-fold) at days 3 and 4 after infection. A 2- to 3-fold decrease in
TIMP-2 and -3 transcripts was observed only at days 3 and 4 aftercell supernatants collected at various time points after infection were determined by
supernatant represent mean ± SD of data obtained from at least three independent
tained with anti-GFAP antibody or anti-WNV envelope antibody, and counterstained
m. (ii) WNV-infected HBCA cells demonstrate robust virus staining in the cytoplasm.
show any immunostaining.
132 S. Verma et al. / Virology 397 (2010) 130–138infection (Fig. 2B). Infection of HBCA cells with UV-WNV did not
induce any change in the expression proﬁle of these genes (data not
shown), further indicating that these alterations were a result of
WNV replication, rather than just virus entry into the cells.
Increase in MMP protein expression
Immunocytochemical analysis did not exhibit increase in MMP-9
immunostaining in mock-infected HBCA cells (Fig. 3A, i); however, a
strong signal of MMP-9 expression was observed at day 3 after
infection in both WNV-infected as well as neighboring un-infected
HBCA cells (Fig. 3A, iii and iv). Further, as depicted in Figs. 3B and C, a
signiﬁcant increase of 50% in the MMP-1 protein expression was ﬁrst
evident at day 2 after infection, and was consistently high at days 3
and 4 after infection. On the other hand, increase in MMP-3 and -9
protein expression was mostly observed at days 3 and 4 after
infection, thus coinciding with the increase in their mRNA transcripts.
MMP-3 and -9 activities are increased in the supernatant of
WNV-infected HBCA cells
Since MMPs are secretory proteins, their increase was further
determined in the supernatant of WNV-infected HBCA cells by
assessing the gelatinolytic activity of MMPs by zymography as well
as ELISA. As depicted in Fig. 4A, the supernatant from mock-infectedFig. 3.WNV induces protein expression of MMPs in HBCA cells. (A) Conﬂuent primary HBCA
immunoﬂuorescence. (i) Mock-infected HBCA cells demonstrated very faint and diffused
antibody did not show any staining. (iii and iv) Marked increase in MMP-9 staining (green
both WNV-infected (red) as well as neighboring un-infected HBCA cells. The images shown
μm at 20× magniﬁcation. (B) Western blot analysis of MMP-1, -3 and -9. Cellular proteins ex
onto PVDF membranes and immunoblotted with antibodies speciﬁc to MMP-1, -3 and -9.
detected by the chemiluminescence method. (C) Quantitative analysis of western blots rep
the corresponding time point. Mean comparisons were based upon extrapolated CI for thr
cells; I, WNV-infected HBCA cells.HBCA cells gave a faint gelatinolytic band of 92-kDa, which became
intense and strong in the supernatant fromWNV-infected HBCA cells.
Densitometric analysis of the intensity of the bands demonstrated a
90% and 208% increase in MMP-9 activity as compared to controls at
days 3 and 4 after infection, respectively (pb0.005, Fig. 4B). Similarly,
MMP-3 enzyme activity determined by casein zymography demon-
strated an increase in its activity by 48% and 56% in WNV-infected
HBCA cells at the same time points (Figs. 4A and B). Interestingly,
MMP-2 band at 72-kDa demonstrated decreased gelatinolytic activity
in WNV-infected HBCA cells at both time points. In addition, total
MMP-9 protein measured by ELISA also increased signiﬁcantly in the
supernatant from WNV-infected HBCA cells at day 3 after infection
(pb0.05, Fig. 4C).
The MMPs released in the supernatant of WNV-infected HBCA cells can
degrade TJP of HBMVE cells
We previously demonstrated that WNV infection of HBMVE cells
has no effect on the key TJPs (Verma et al., 2009). To determine the
ability of HBCA-derived MMPs to digest TJP, naïve HBMVE cells were
either infected directly with WNV or incubated with supernatant
media from mock- or WNV-infected HBCA cells. As observed in Fig.
5A, naïve HBMVE cells demonstrated distinct ZO-1 staining at the cell
borders (i and ii), which did not change in response to direct WNV
infection, at days 3 and 4 after infection (iii and iv). Further, ZO-1cells were infected with WNV at MOI-5 and MMP-9 expression was determined using
MMP-9 immunoreactivity (green). (ii) Mock-infected cells incubated without MMP-9
) was observed at day 3 in WNV-infected HBCA cells. MMP-9 increase was evident in
are representative results of three independent experiments. Scale bar represents 10
tracted fromWNV- and mock-infected HBCA cells were separated on PAGE, transferred
The membranes were stripped and re-probed with anti-β-actin and the bands were
resented as percentage increase in MMPs compared to respective control HBCA cells at
ee data points. ⁎pb0.05, compared to corresponding controls. C, mock-infected HBCA
Fig. 4.WNV infection induces enzymatic activities of MMP-3 and -9 in HBCA cells. (A)
The conditioned media from WNV- and mock-infected HBCA cells were analyzed for
MMP-2/9 and -3 enzyme activities by gelatin and casein zymography, respectively. (B)
The densitometric analysis demonstrates signiﬁcant increase in MMP-3 and -9
activities in infected HBCA cells. (C) Total MMP-9 levels were measured by ELISA in
the supernatant from mock- and WNV-infected HBCA cells at day 3 after infection.
Mean comparisons were based upon extrapolated CI for three data points. Values
represent mean ± SD. ⁎pb0.005, ⁎⁎pb0.05 compared to corresponding control cells.
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natant from mock-infected HBCA cells (Fig. 5A, v and vi) was similar
to naïve HBMVE cells (i and ii); however, HBMVE cells treated with
supernatant from WNV-infected HBCA cells, collected at day 3 after
infection, demonstrated distinct loss of ZO-1 protein, which became
even more prominent when incubated with supernatant from WNV-
infected HBCA cells collected at day 4 after infection (Fig. 5A, vii and
viii). To further conﬁrm the speciﬁcity of MMPs in the degradation of
TJP, the supernatant from mock- and WNV-infected HBCA cells was
treated with broad-spectrum MMP inhibitor GM6001 for 15 min
before incubation with naïve HBMVE cells. While the incubation of
naïve HBMVE cells with supernatant from mock-infected HBCA cells
treated with GM6001 did not affect ZO-1 staining (Fig. 5A ix and x),
loss of ZO-1 was noticeably reversed in the naïve HBMVE cellsincubated with GM6001-treated supernatant from WNV-infected
HBCA cells collected at both days 3 and 4 after infection (Fig. 5A, xi and
xii). Gelatin zymography of GM6001-treated supernatant fromWNV-
infected HBCA cells demonstrated a distinct loss of MMP-2 and -9
enzyme activities as compared to the untreated supernatant, thereby
conﬁrming the ability of GM6001 to block MMP-9 enzyme activity
(Fig. 5A, inset).
Expression of claudin-1 is also critical for maintaining the BBB
integrity. Therefore, in addition to ZO-1 we also investigated the
expression of claudin-1 in HBMVE cells by immunostaining to further
understand the effect of MMPs on BBB integrity parameters. As
compared to naïve HBMVE cells (Fig 5B, i and ii), expression of
claudin-1 increased at days 3 and 4 after WNV infection of HBMVE
cells (Fig. 5B, iii and iv), which concurs with our previous observation
(Verma et al., 2009). However, similar to ZO-1 (Fig. 5A), claudin-1
expression, which did not change in the presence of supernatant from
mock-infected HBCA cells (Fig. 5B, v and vi), decreased considerably
in the presence of supernatant from WNV-infected HBCA cells
collected at days 3 and 4 after infection (Fig. 5B, vii and viii) and the
treatment of supernatant with GM6001 markedly reversed the
degradation of claudin-1 induced by supernatant from WNV-infected
HBCA cells (Fig. 5B, xi and xii). To further differentiate betweenMMP-
induced degradation of TJP and cytotoxicity triggered by HBCA
supernatant, the cytotoxicity assays were performed on HBMVE
cells after similar treatments and no signiﬁcant change in the cell
viability of HBMVE cells was observed (data not shown).
Integrity of the BBB model compromised by MMPs secreted by
WNV-infectedHBCA cells can be reversed in the presence ofMMP inhibitor
Disruption of the BBB is mostly associated with degradation or
redistribution of TJP. Using BBB model, we previously demonstrated
that directWNV infection of HBMVE cells per se does not compromise
the BBB integrity (Verma et al., 2009). In this study, we employed
similar model to investigate if MMPs derived from infected HBCA cells
can degrade ZO-1 and claudin-1 of HBMVE cells and compromise the
BBB integrity. At day 8 after seeding, the integrity of the BBB models
demonstrated high TEER (650 Ω/cm2) and low dextran transmigra-
tion (2–3%) as compared to inserts with no cells. The BBB models
incubated with synthetic MMP-9 (10 ng/mL media) as positive
controls for 6 h resulted in a signiﬁcant decrease in the TEER (Fig. 6A).
The BBB models were then incubated for 6 h with cell supernatants
from HBCA cells collected at day 4 after infection. While the TEER of
the BBB models incubated with the supernatant from mock-infected
HBCA cells did not change as compared to control models (only
HBMVE cell media), it decreased signiﬁcantly (∼400Ω/cm2, pb0.005)
in the BBB models incubated with supernatant from WNV-infected
HBCA cells (Fig. 6A). Treatment of WNV-infected HBCA cell super-
natant with GM6001 prior to the incubation restored the TEER values
(pb0.05). Similarly, there was no signiﬁcant change in the FITC-
dextran transmigrated across the BBB models incubated with super-
natant from mock-infected HBCA cells as compared to control BBB
models with only CSC media (Fig. 6B). However, BBB models incu-
bated with supernatant fromWNV-infected HBCA cells demonstrated
a signiﬁcant increase in the percent FITC-dextran transmigration
(190%, pb0.005) as compared to controls, and the treatment of
supernatant with GM6001 signiﬁcantly inhibited FITC-dextran trans-
migration from 190% to 140% (pb0.05).
Discussion
The tight junctions of the BBB play a critical role in preserving the
integrity of the BBB and restricting the entry of immune cells as well
as pathogens into the CNS. Increased permeability of the BBB is
shown to be associated with increased WNV titers in the brain
(Diamond and Klein, 2004). This study characterizing the acute MMP
Fig. 5.WNV-inducedMMPs lead to degradation of TJP of HBMVE cells. Conﬂuent primary HBMVE cells were either infectedwithWNV or incubated with the supernatant frommock-
or WNV-infected HBCA cells for 6 h and TJP expression was visualized using confocal immunoﬂuorescence microscopy. (A) ZO-1 staining in (i and ii) naïve HBMVE cells
characterized by staining at cell borders did not change as a result of (iii and iv) WNV infection or (v and vi) after incubation of naïve HBMVE cells with supernatant media from
mock-infected HBCA cells collected at days 3 and 4 after infection. Whereas there was a distinct loss of ZO-1 staining in naïve HBMVE cells incubated with supernatant media from
WNV-infected HBCA cells at days 3 and 4 after infection (vii and viii). The treatment of supernatant media from mock-infected HBCA cells with GM6001 had no effect on ZO-1
staining (ix and x); however, disrupted ZO-1 staining was markedly reversed in naïve HBMVE cells incubated with GM6001-treated supernatant from WNV-infected HBCA cells at
days 3 and 4 after infection (xi and xii). The inset depicts MMP-9 activity in (a) supernatant of infected HBCA cells and (b) in the presence of GM6001. (B) Immunostaining of claudin-
1 in HBMVE cells by WNV-induced MMPs. Claudin-1 immunoreactivity which was characterized by intracellular and junctional pattern in (i and ii) naïve HBMVE cells, increased at
days 3 and 4 after (iii and iv) WNV infection. (v and vi) Incubation of naïve HBMVE cells with supernatant frommock-infected HBCA cells for 6 h did not alter the claudin-1 staining
pattern; however, (vii and viii) incubation with supernatant from WNV-infected HBCA cells at days 3 and 4 after infection disrupted the claudin-1 staining. Effect of GM6001
treatment on supernatant from (ix and x)mock-infected and (xi and xii)WNV-infected HBCA cells on the claudin-1 immunostaining. The images shown are representative results of
at least three independent experiments in duplicate. Scale bar represents 20 μm at 63× magniﬁcation.
134 S. Verma et al. / Virology 397 (2010) 130–138gene and protein changes as a result of WNV infection of BBB cells
highlights that astrocytes are one of the potential source of multiple
MMPs, which degrade key TJPs of HBMVE cells and compromise the
integrity of the BBB model thereby contributing to WNV-associated
neuropathogenesis.
Recently, non-neuronal brain cells such as astrocytes, microglia
and brain endothelial cells have also been shown to be susceptible to
WNV infection (Cheeran et al., 2005; van Marle et al., 2007). Presence
of WNV antigen has been recently demonstrated in the astrocytes of
WNV-infected human brain tissue (van Marle et al., 2007). In our
study, the WNV infection kinetics seen in HBCA cells is similar to the
results observed in the previous studies of WNV infection in
astrocytes (Cheeran et al., 2005; van Marle et al., 2007). Increased
MMP-9 activity has been recently reported in the CSF of WNV-
infected patients as well as in mice brain (Wang et al., 2008).However, the question remains, what is the speciﬁc cell source of
MMPs in the brain and their precise role in modulating BBB tight
junction properties. In other neuroinﬂammatory diseases such as MS,
cerebral ischemia, Alzheimer's disease and virus infections such as
HIV, human herpesvirus-8 (HHV-8), and HTLV, increase inMMP-9 has
been reported in brain endothelial cells (Chaudhuri et al., 2008;
Conant et al., 1999; Cunningham, Wetzel, and Rosenberg, 2005;
Ottino et al., 2004; Qian et al., 2007; Rosenberg, 1995; Rosenberg and
Yang, 2007; Sellner et al., 2006; Shigemori et al., 2006; Sporer et al.,
2000). As compared to these disease scenarios, our data demonstrate
no alterations in the expression of MMPs or TIMPs in WNV-infected
HBMVE cells and neuronal cells (data not shown). This observation, in
context with our previous data indicating either no degradation of any
TJP (Verma et al., 2009) or no signiﬁcant induction of inﬂammatory
cytokines (data not shown) in WNV-infected HBMVE cells, suggest
Fig. 6. Supernatant from WNV-infected HBCA cells augment the paracellular perme-
ability of the BBB model. At day 8 after seeding, the BBB models were incubated with
supernatant from mock- and WNV-infected HBCA cells or synthetic MMP-9 enzyme as
positive control for 6 h. (A) The integrity of the BBB models was determined by
measuring the TEER before and after the incubation. TEER values, presented as Ω/cm2,
demonstrated a signiﬁcant decrease only in the BBB model incubated with either
supernatant from WNV-infected HBCA cells or synthetic MMP-9 enzyme. Presence of
GM6001 rescued the BBB permeability. (B) FITC-dextran permeability assay of the BBB
models. After 6 h of incubation, the percentage of FITC-dextran that crossed the BBB
models as compared to control BBB models did not vary signiﬁcantly in BBB models
incubated with supernatant from mock-infected HBCA cells. BBB models incubated
with supernatant from WNV-infected HBCA cells demonstrated signiﬁcant increase in
the FITC-dextran transmigration and this increase was reversed in presence of GM6001.
The data are representative of at least three independent experiments in duplicate.
⁎pb0.005, percent change as compared to control inserts; ⁎⁎pb0.05, percent change of
GM6001-treated supernatants as compared to corresponding BBB models without
GM6001 treatment.
135S. Verma et al. / Virology 397 (2010) 130–138that speciﬁc host defense response of HBMVE cells to WNV infection
most likely is protective in vivo and might provide a barrier to the
WNV–CNS entry, which fails in vivo due to the neuroinﬂammatory
mediators secreted by other cells.
Activation of glial cells is a key pathogenic feature of WNV-
associated meningoencephalitis (Cheeran et al., 2005; Diniz et al.,
2006; van Marle et al., 2007). Recent data by van Marle et al. (2007)
provide direct evidence for the role of neurotoxic mediators released
by WNV-infected astrocytes in causing neuronal cell death. Both in
vitro and in vivo resident astrocytes have been demonstrated to
respond to neuropathological injuries and undergo functional
changes including increased production of MMPs (Anthony et al.,
1997; Chaudhuri et al., 2008; Leppert et al., 2001; Rosenberg, 2002). In
this report, the peak increase in both mRNA expression as well as
enzyme activities detected between days 2 and 4 after infection when
the virus titers were also high strongly suggests that MMP production
is triggered by virus replication, not merely by virus entry. Theactivities of MMPs are tightly controlled at the level of mRNA
expression, zymogen activation and an imbalance in the ratio between
TIMP andMMPwhich determines the extent of the degradation of the
extracellular matrix (Cunningham,Wetzel, and Rosenberg, 2005). Our
data demonstrating elevated levels of MMP-1, -3 and -9 along with
reduced level of TIMP-2 in WNV-infected HBCA cells indicate a clear
imbalance in their ratios.
Another observation in our data was that WNV induced multiple
MMPs in HBCA cells. Even though the exact role of individual MMPs is
unclear, it is likely that MMP-1 and -3 also contribute to the BBB injury
either by directly digesting TJP or by activating pro-MMP-9 to active
MMP-9. Several novel roles of MMP-1 and -3 have been described
recently such as triggering neuroinﬂammation (Mun-Bryce et al.,
2002; Suzuki et al., 2007), apoptosis (Kim et al., 2005) and direct
activation of pro-MMP-9 (Conant et al., 2002). Based on our data
demonstrating increase in MMP-3 and decrease MMP-2 activity, we
speculate that the activation of MMP-9 in WNV-infected astrocytes is
via MMP-3.
The kinetics of TJP expression during WNV infection has not been
characterized. In this report, we for the ﬁrst time demonstrate that
degradation of TJP of HBMVE cells is mediated by MMPs derived from
WNV-infected astrocytes. In addition, we have used a BBB model to
demonstrate that the loss of TJP by MMPs directly results in decreased
TEER and increased FITC-dextran transmigration representing loss of
membrane integrity. In vitro BBBmodels are routinely used to asses the
effect of virus infections or transmigration of virus-infected immune
cells on the BBB permeability (Kanmogne et al., 2007; Mahajan et al.,
2008; Persidsky et al., 1997). Such degradation of TJP byMMPs released
by infected macrophages and glial cells has been shown in infections
with other neurotropic viruses such as HIV (Johnston et al., 2001;
Sporer et al., 2000). Similarly, decreased degradation of collagen IV, an
important component of the basement membrane in WNV-infected
MMP-9−/− mice as compared to wild-type mice was observed by
Wang et al. (2008). Based on these observations, we believe that in
vivo, theseWNV-induced MMPs derived from astrocytes contribute to
BBB disruption by degrading components of both basement mem-
branes as well as tight junctions ultimately resulting in inﬁltration of
virus and immune cells into the CNS.
TNF-α is another well known mediator of BBB disruption and
responds signiﬁcantly to WNV infection (Cheng, King, and Kesson,
2004;Wang et al., 2004). In HBCA cells too,WNV infection signiﬁcantly
induces TNF-α from days 1 to 4 after infection (data not shown).
However, our data suggesting the role of HBCA-derived MMPs in
directly disrupting the tight junctions are further strengthened by the
fact that GM6001 can efﬁciently block the TJP degradation and BBB
disruption. GM6001 is a broad-spectrum MMP inhibitor and is
routinely used in in vitro as well as in vivo models to understand
their pathogenic roles (Chen et al., 2006; Zozulya et al., 2007).
Treatment of mice with GM6001 (Ilomastat) has shown to reduce/
delay BBB disruption and neuroinﬂammation resulting in improved
disease outcome of several neurodegenerative disease models such as
cerebral ischemia and infection with HIV and Semliki forest virus
(Amantea et al., 2007; Johnston et al., 2001; Keogh et al., 2003). In
addition, LPS-induced disruption of the BBB is reported to be reversed
signiﬁcantly in the presence of MMP inhibitors including GM6001
(Mun-Bryce andRosenberg, 1998; Rosenberg, Estrada, andMobashery,
2007). Due to the ability of MMP inhibitors to improve disease
symptoms, speciﬁc synthetic MMP inhibitors have been used or
proposed as short term supporting therapies for acute inﬂammatory
diseases such as MS, BM and vascular inﬂammatory diseases (Leppert
et al., 2001; Mandal et al., 2003; Yong et al., 2007).
In summary, our results emphasize that complex neuroinﬂamma-
tory responses associated withWNV infection in the CNS aremediated
by astrocytes as one of the key players, and involve up-regulation of
several MMPs. Though WNV-induced TJP degradation remains to be
validated in in vivo mouse model, we conclude that MMP-induced
136 S. Verma et al. / Virology 397 (2010) 130–138perturbations in the TJP expression might be an important pathway in
WNV-induced BBB injury in vivo, resulting in complex downstream
pathological events such as the unrestricted entry of infected and/or
activated inﬂammatory and immune cells as ‘Trojan horse’ into the
CNS. The ability of GM6001 to rescue the BBB permeability is
encouraging and the therapeutic use of MMP inhibitors to block
WNV-associated BBB injury, inﬂammation and CNS inﬁltration of
infected or activated immune cells in vivo is warranted.
Materials and methods
Cells, virus and plaque assay
Primary HBCA cells were obtained from ACBRI (Kirkland, WA) and
propagated in the astrocyte media (ATCC) while HBMVE cells were
grown as described previously (Chapagain et al., 2007). Only early
passage primary HBCA and HBMVE cells (passages 6–9) were used for
all experiments. WNV strain NY99 was used for all infection
experiments at MOI-5 as described previously (Verma et al., 2009;
Verma et al., 2008). Production of infectious virus in the supernatant
was determined by plaque assay (Verma et al., 2008).
qRT-PCR analysis
cDNA prepared from RNA extracted from WNV-, UV-WNV-, and
mock-infected HBCA and HBMVE cells was used for qRT-PCR as
described previously (Verma et al., 2009; Verma et al., 2008; Verma
et al., 2006). Primer sequences and annealing temperatures used for
ampliﬁcation of MMPs and TIMP are described in Table 1.
Western immunoblot analysis
Total 40–50 μg of cellular protein extracted from mock-infected
HBCA cells at days 2–4 after infection were used for western
blotting (Verma et al., 2009; Verma et al., 2008). The membranes
were incubated with antibodies against rabbit polyclonal anti-MMP-1
(1mg/mL, Chemicon), mouse polyclonal anti-MMP-3 (1:1000, Calbio-
chem) and rabbit polyclonal anti-MMP-9 (1:1000, Abcam) followed by
HRP-conjugated secondary antibodies, and were developed using ECL
detection kit and analyzed by Bio-Rad Quantity One Program.Table 1
Primer sequences used for qRT-PCR.
Gene (GenBank no.) Primer sequence (5′-3′) Amplicon
(bp) Tm (°C)
MMP1 (NM_002421)
Forward ATGAAGCAGCCCAGATGTG 98 55
Reverse TCAATCCTGTAGGTCAGATGTG
MMP2 (NM_004530)
Forward TGCTGAAGGACACACTAAAGAAG 147 55
Reverse CTTGCGAGGGAAGAAGTTGTAG
MMP3 (NM_002422)
Forward TCCTGGCATCCCGAAGTG 146 57
Reverse AGCCTGGAGAATGTGAGTGG
MMP9 (NM_004994)
Forward GCCACTTCCCCTTCATCTTCG 168 56
Reverse ATTGCCGTCCTGGGTGTAGAG
TIMP-1 (M12670)
Forward TGTTGGCTGTGAGGAATGCA 84 55
Reverse GGTCCGTCCACAAGCAATG
TIMP-2 (NM_003255)
Forward CGTTGGAGGAAAGAAGGAATATC 86 55
Reverse GCACGATGAAGTCACAGAGG
TIMP-3 (U67195)
Forward GCGTCTATGATGGCAAGATG 148 55
Reverse AAGCAAGGCAGGTAGTAGCMMP-3 and -9 enzyme activity analysis by zymography and ELISA
At days 3 and 4 after infection, the supernatant medium from
HBCA cells was collected for zymography and ELISA assays. For
zymography, the supernatant was concentrated 10-fold using Micro-
con centrifugal ﬁlter units (Millipore) and electrophoresed on 10%
SDS–polyacrylamide gels containing 1 mg/mL gelatin or casein as a
protease substrate and the gelatinolytic bands were determined as
described previously (Chua et al., 2003). ELISA for total MMP-9 in the
supernatant from mock- and WNV-infected HBCA cells at day 3 after
infection was performed using Quantikine human MMP-9 ELISA kit
according to the manufacturers' instructions (R&D Systems), and a
standard curve was generated in the range of 0–20 ng/mL. The plates
were read using a Victor 3 microtiter reader equipped with Workout
1.5 software (Perkin Elmer).
Treatment of HBMVE cells with supernatant of HBCA cells
and cytotoxicity assays
HBMVE cells grown on coverslips were incubated for 6 h with
supernatant from aforementioned mock-infected HBCA cells. Brieﬂy
250 μL of the supernatant from HBCA cells was mixed with 250 μL of
the CSC media of HBMVE cells and applied to naïve HBMVE cells.
HBCA media collected on days 3 and 4 after infection were treated
with broad-spectrum MMP inhibitor GM6001 (25 μM/mL, Calbio-
chem) for 15 min at room temperature before applying to naïve
HBMVE cells. Following incubation, the cells were washed twice with
1× PBS and ﬁxed with 4% PFA. Similar treatments were performed on
HBMVE cells grown in 96-well plate and cell viability was assayed as
described previously (Verma et al., 2008).
Immunocytochemical analysis
Fixed HBCA cells were immunostained using monoclonal anti-
WNV envelope (1:800), polyclonal anti-GFAP (1:100, Chemicon) or
anti-MMP-9 (1:100) antibodies followed by secondary antibodies
conjugated with Alexa Fluor 546 (GFAP and WNV) or FITC (MMP-9).
HBMVE cells with or without treatment with supernatant from HBCA
cells were immunostained with monoclonal mouse anti-ZO-1 or
polyclonal rabbit anti-claudin-1 (Verma et al., 2009).
Development of BBB model and WNV infection
An in vitro monolayer BBB model composed of HBMVE cells was
developed on a BioCoat® Cell Environment™ Human Fibronectin
PET (polyethylene terephthalate) insert with 3.0 μm pore size in a
24-well plate (BD Bioscience, Bedford, MA) as described previously
(Verma et al., 2009). The integrity of the in vitro BBB model was
determined every day, as described previously (Verma et al., 2009).
The FITC-dextran (4-kDa MW) transmigration across the inserts was
calculated as percentage of the total amount added in the upper well
(10 μg/100 μL) and the TEER was measured using EVOMX and was
expressed asΩ/cm2. At day 8 after seeding, upper and lower chambers
of the BBBmodelswere incubatedwith 400 μL of the supernatant from
HBCA cells collected at day 4 after infection in the presence or absence
of GM6001 (25 nM/mL). After 6 h of incubation, the models were
washed twice with 1× PBS and the BBB integrity was assayed by TEER
and FITC-dextran transmigration assay. For positive control, the inserts
were treated with synthetic MMP-2/9 enzyme (10 μg/membrane).
Statistical analysis
Data are reported asmean±standard error ofmean of at least three
independent experiments. Unpaired Student t-test using GraphPad
Prism 5.0 (GraphPad software) was used to compare the values of
arbitrary units of densitometry scans and permeability assays.
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